Thermal ablation: cost-effective and safe for the treatment of cervical precancer (IARC Evidence Summary Brief No. 7)

Evidence from 15 years of research by the International Agency for Research on Cancer (IARC) has shown that a new portable, low-cost, battery-powered device, a thermal ablator co-developed by IARC and a team of engineers, is as effective and safe in treating cervical precancers as current standard-of-care methods.

In its seventh Evidence Summary Brief, IARC highlights key findings from multiple studies conducted in research and programmatic settings that generated evidence on the efficacy, safety, feasibility, scalability, and cost–effectiveness of thermal ablation. This new Evidence Summary Brief calls on policy-makers to continue supporting the deployment of the device, particularly in low- and middle-income countries.

This IARC Evidence Summary Brief is the seventh in a series of scientific Evidence Summary Briefs published by IARC to call attention to the findings of evidence-based studies in key aspects of cancer prevention.

Read IARC Press Release 373

Read IARC Evidence Summary Brief No. 7

Read more about the IARC Evidence Summary Briefs series